Orthofix Medical (OFIX) Research & Development (2010 - 2026)

Orthofix Medical has disclosed Research & Development across 17 years of filings, most recently posting $15.3 million for Q1 2026.

• Quarterly Research & Development fell 22.49% year-over-year to $15.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.4 million (down 16.93% YoY) and the FY2025 annual result came in at $65.8 million, down 10.59% from the prior year.
• Research & Development held at $15.3 million in Q1 2026, from $15.4 million in the prior quarter.
• Over five years, Research & Development peaked at $23.3 million in Q1 2023 and troughed at $11.2 million in Q1 2022.
• A 5-year average of $16.7 million and a median of $17.3 million in 2024 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development surged 107.88% — and 2026, when it retreated 22.49%.
• Tracing OFIX's Research & Development over 5 years: stood at $13.2 million in 2022, then soared by 44.02% to $18.9 million in 2023, then declined by 0.7% to $18.8 million in 2024, then dropped by 18.26% to $15.4 million in 2025, then dropped by 0.34% to $15.3 million in 2026.
• Business Quant data shows OFIX's Research & Development at $15.3 million in Q1 2026, $15.4 million in Q4 2025, and $14.8 million in Q3 2025.